Fujitsu launched a new cloud-based platform that allows users to securely collect and leverage health-related data.
The new platform automatically converts medical data from medical institutions' electronic medical records to conform with the next-generation standards framework HL7 FHIR,
Consenting patients can securely store personal health information such as vital data, step counts, and calorie consumption.
These are converted into non-personally identifiable information on the platform, which supports medical institutions and pharmaceutical companies in performing data analysis and R&D activities.
The new offering represents Fujitsu’s ongoing efforts to promote digital transformation in the medical field and contribute to the creation of a healthy society.
Fujitsu will also use the platform to develop a data portability service that enables patients to view their medical data on their smartphones and allows medical institutions to conduct a highly accurate analysis of shared medical data on the platform.
Fujitsu said it aims to leverage this platform to realize an AI and IoT-based preventive healthcare system and cooperate with various medical institutions and companies to realize a digital health ecosystem.


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Washington Post Publisher Will Lewis Steps Down After Layoffs
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Instagram Outage Disrupts Thousands of U.S. Users
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 



